Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18044777 | 0.92 | TYR (0.50) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL10825810 | 0.89 | TYR (0.55) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL31613067 | 0.89 | TYR (0.55) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL5377617 | 0.88 | TYR (0.72) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL18044778 | 0.86 | TYR (0.48) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL10822716 | 0.85 | TYR (0.52) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL9156290 | 0.85 | TYR (0.52) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL68200 | 0.83 | TYR (0.77) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL29684238 | 0.83 | TYR (0.77) | TYRMEN1TP53CYP3A4ALOX5 | |
| SCHEMBL5381354 | 0.83 | TYR (0.48) | TYRMEN1TP53CYP3A4ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202359-B2 | Azaoxa heterocyclic compound and method of preparing the same | CHANG CHUN PLASTICS CO., LTD. (TW) | 2007-04-10 | — | — | US | disclosed |
| CN-1234706-C | Nitrogen-oxygen heterocyclic compound and preparation method thereof | CHANGCHUN ARTIFICIAL RESIN FAC (CN) | 2006-01-04 | — | — | CN | disclosed |
| US-20050085634-A1 | Azaoxa heterocyclic compound and method of preparing the same | CHANG CHUN PLASTICS CO., LTD. (TW) | 2005-04-21 | — | — | US | disclosed |
| CN-1490318-A | Nitrogen-oxygen heterocyclic compound and preparation method thereof | 长春人造树脂厂股份有限公司 | 2004-04-21 | — | — | CN | disclosed |
| US-20040068084-A1 | Azaoxa heterocyclic compound and method of preparing the same | CHANG CHUN PLASTICS CO., LTD. (TW) | 2004-04-08 | — | — | US | disclosed |
| US-6211328-B1 | IN PRESENCE OF AN ACID | GUN EI CHEMICAL INDUSTRY CO., LTD (JP) | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068084-A1 | Azaoxa heterocyclic compound and method of preparing the same | AOX1, KDM1A, BMI1 | TYR 485/4885MEN1 3378/4885TP53 3505/4885 |
| US-20050085634-A1 | Azaoxa heterocyclic compound and method of preparing the same | AOX1, KDM1A, BMI1 | TYR 314/4885MEN1 3668/4885TP53 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.